JW gains solid tumor technology license through recent acquisition
By Nikita Chaurasia  Date: 2020-07-21

JW gains solid tumor technology license through recent acquisition

JW Therapeutics, a biotechnology company headquartered in Shanghai, China, has reportedly acquired Syracuse Biopharma (Hong Kong) Ltd., inclusive of a licensing agreement for Eureka Therapeutics’ solid tumor technology and ARTEMIS® antibody TCR for exclusive use in China and ASEAN nations.

Earlier this month, JW Therapeutics collaborated with Acepodia for the commercialization of two of company’s cell therapy candidates for treating solid tumors and hematologic malignancies.

Dr. James Li, Co-Founder and Head of JW Therapeutics, stated that the company is excited to declare the acquisition of Syracuse for strengthening its clinical expertise in solid tumor cancers. Syracuse and Eureka have devised a unique and effective approach for treating solid tumors with their T-cell receptor antibody mimic antibody (TCRm-Ab) and ARTEMIS® technologies. The company is looking to forward to work with them to deliver the next generation of T cell immunotherapies to patients, he added.

On the other side, Founder and CEO of Eureka Therapeutics, Dr. Cheng Liu is equally excited to work with JW Therapeutics for having recognized the value of the propriety ARTEMIS® platform. With the help of JW, the company is looking to leverage the new-found resources to speed up the development of T cell therapies for its battle against solid tumors.

The number of hepatocellular carcinoma (HCC) cases in China is very high and JW is strategically positioned to develop these therapies and increase its accessibility to patients across China, he added.

Founder and President of Eureka Therapeutics, Dr. Cheng Liu, will now be a part of the Board of Directors at JW Therapeutics, while the Chief Business Officer and General Counsel of Eureka, Victor Shum, will take on the role of a Board Observer, claim credible sources.

The terms of the deal have not been disclosed so far.

Sources: https://www.businesswire.com/news/home/20200720005179/en/JW-Therapeutics-Acquires-Syracuse-Biopharma-License-Eureka

https://www.globenewswire.com/news-release/2020/07/14/2061786/0/en/Acepodia-and-JW-Therapeutics-Enter-into-Option-and-License-Agreement-for-Off-the-shelf-NK-Cell-Therapies.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Borqs Technologies introduces BeSmartTrack™ for tracing COVID-19 virus
Borqs Technologies introduces BeSmartTrack™ for tracing COVID-19 virus
By Nikita Chaurasia

Lately, China-based leading developer of software application for IoT (Internet of Things) Borqs Technologies Inc. has gained significant attention upon launching its mobile smart tracking solution called BeSmartTrack™. The launch event reporte...

Fractyl raises series E funding of USD 55 million for diabetes cure
Fractyl raises series E funding of USD 55 million for diabetes cure
By Nikita Chaurasia

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes. As per the trusted sources, the capital will be invested on mass-b...

Nokia Corp. partners with IISc to improve telecommunication solutions
Nokia Corp. partners with IISc to improve telecommunication solutions
By Nikita Chaurasia

Finnish multinational telecommunications giant Nokia Corporation has recently made it to the headlines after entering into a joint venture agreement with IISc (Indian Institute of Science) to launch the Nokia CoE (Centre of excellence) for Networked ...

Motorola acquires Pelco Inc. to expand its video security services
Motorola acquires Pelco Inc. to expand its video security services
By Nikita Chaurasia

Chicago-based telecommunication company, Motorola Solutions Inc., has made it to the headlines through its acquisition of Pelco Inc. from Transom Capital Group for $110 million dollars. For those uninitiated, Pelco Inc. is a security and surveillanc...

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
By Nikita Chaurasia

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures a...